-Bloomberg
SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $68
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $66 to $68.
Related Posts
IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs
IBio Inc (NYSE:IBIO) has added three anti-cancer targets to its pipeline of therapeutic candidates. The Company seeks to change the drug…
Recap: Newtek Business Services Q4 Earnings
Newtek Business Services (NASDAQ:NEWT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
‘Tesla Giga Berlin is aiming for 2,000 Model Y per week: report’ -Teslarati Report
https://www.teslarati.com/tesla-giga-berlin-2k-model-y-per-week-september-report/